Data Monitoring Committees (DMCs) review data from ongoing clinical trials and make recommendations based on risk-benefit and other criteria — they are an essential component to help protect the safety of current and potential patients. However, while the ethical benefits of including a DMC are well-discussed, less so are the financial considerations of DMCs.

Key topics

In this webinar, we will delve into the following overarching themes:

• The overall cost of the DMC, including such considerations as membership size, cadence, outputs for review, programming model, and so on.
• The potential savings of early stopping (for efficacy, futility, or safety), compared to the average cost of the DMC.

This webinar should prove instructive to organizations that wish to have a DMC that not only protects patients, but does so in an efficient manner both within the DMC domain, as well as at the higher study and clinical program level.

Speaker

David Kerr, DMC Biostatistician Director